Life Sciences Group to Have Strong Presence at 2017 BIO International Convention
Toronto (June 19, 2017) — Borden Ladner Gervais (BLG) is pleased to release the fourth annual edition of its report, Life Sciences Legal Trends in Canada (Life Signs). The report features key insights from the Life Sciences team at BLG, as well as messages from Canada's leading national and regional life sciences associations.
BLG's Life Signs report covers notable trends in the areas of Intellectual Property, Regulatory Affairs, Privacy and Cybersecurity, as well as Capital Markets, and includes articles on topics such as diagnostic inventions, CETA implications, pharmaceutical trademark protection, cannabis oil, cyber risk management and sandbagging in M&A.
"With 12 representatives attending this year's BIO International Convention in San Diego, BLG's Life Sciences Group looks forward to engaging in a meaningful discussion with industry leaders on these significant issues," said Jeffrey Graham, national leader of BLG's Life Sciences Group.
BLG's life sciences practice extends from bench top to boardroom, providing strategic advice to clients across the spectrum of the sector. The firm's multi-disciplinary life science group advises entrepreneurs and investors involved in the commercialization of life sciences technologies, as well as domestic and international clients with products in sale, including drugs, medical devices, natural health products, biomaterials, ag-biotech products and well as companies with energy/environmental applications.
For those attending the BIO International Convention in San Diego, BLG invites you to visit Booth 4715, or contact Paul Fortin, Director of International Business Development, at [email protected].